Prostate Stem Cell Antigen (PSCA) is a highly validated glycosylphosphatidylinositol (GPI)-anchored cell surface antigen. Overexpressed in prostate cancer, pancreatic cancer, and gastric cancer, PSCA represents a major therapeutic node for next-generation biologics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSCA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSCA ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View PSCA Products |
| Gene Delivery | PSCA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (FACS and CAR-T validation). |
View PSCA Products |
| Benchmark Ab | Anti-PSCA Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View PSCA Products |
| Validator | PSCA siRNA Set For target knockdown and specificity verification in vitro. |
View PSCA Products |
| Related Target A | STEAP1 Co-expressed prostate cancer cell surface metalloreductase; ideal for combination therapy or bispecific targeting. |
View STEAP1 Products |
| Related Target B | MSLN GPI-anchored tumor antigen sharing structural and trafficking similarities with PSCA; crucial for specificity counter-screening. |
View MSLN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPI-Anchored Target | Lentivirus-driven stable cell lines preserve the native GPI-anchored cell surface conformation required for functional screening. |
| Off-Target Cross-Reactivity Risk | Homolog/family panel proteins (such as MSLN) are strictly verified by mass spectrometry to support counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included to calibrate binding and internalization kinetics. |
| False Positives in Screening | Validated siRNA knockdown sets included to confirm target-specific binding in complex cell-based assays. |
Live PSCA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSCA therapeutics is intensifying, with major players shifting focus from traditional mAbs to CAR-T cell therapies, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). As first-generation therapies reach the clinic, the next wave of R&D is targeting solid tumors beyond prostate cancer, including pancreatic and gastric malignancies, where PSCA is highly overexpressed. Overcoming the immunosuppressive tumor microenvironment and establishing reliable, native-conformation assay platforms remain pivotal for clinical success.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T | City of Hope, Bellicum Pharmaceuticals | Prostate Cancer, Pancreatic Cancer | High-titer Lentivirus for stable target expression to validate CAR-T cytolytic activity. |
| ADC | Astellas Pharma, Agensys | Urothelial Cancer, Gastric Cancer | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc protein). |
| Bispecific / BiTE | Amgen, Academic Institutions | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Dual-affinity validation requiring cross-reactive cynomolgus and human PSCA antigens. |